Lenalidomide for the Treatment of Low- or Intermediate-1-Risk Myelodysplastic Syndromes Associated with Deletion 5q Cytogenetic Abnormality: An Evidence Review of the NICE Submission from Celgene

Hedwig M. Blommestein, Nigel Armstrong, Steve Ryder, Sohan Deshpande, Gill Worthy, Caro Noake, Rob Riemsma, Jos Kleijnen, Johan L. Severens, Maiwenn J. Al

Research output: Contribution to journalArticleAcademicpeer-review

1 Citation (Scopus)
Original languageEnglish
Pages (from-to)23-31
Number of pages9
JournalPharmacoeconomics
Volume34
Issue number1
DOIs
Publication statusPublished - Jan 2016

Keywords

  • LENALIDOMIDE
  • Best Suoortive Care
  • Evidence Review Group
  • Acute Myeloid Leukemia
  • Appraisal Committee

Cite this

Blommestein, Hedwig M. ; Armstrong, Nigel ; Ryder, Steve ; Deshpande, Sohan ; Worthy, Gill ; Noake, Caro ; Riemsma, Rob ; Kleijnen, Jos ; Severens, Johan L. ; Al, Maiwenn J. / Lenalidomide for the Treatment of Low- or Intermediate-1-Risk Myelodysplastic Syndromes Associated with Deletion 5q Cytogenetic Abnormality : An Evidence Review of the NICE Submission from Celgene. In: Pharmacoeconomics. 2016 ; Vol. 34, No. 1. pp. 23-31.
@article{0d6737be76bf4a4587d5bc233de0c00e,
title = "Lenalidomide for the Treatment of Low- or Intermediate-1-Risk Myelodysplastic Syndromes Associated with Deletion 5q Cytogenetic Abnormality: An Evidence Review of the NICE Submission from Celgene",
keywords = "LENALIDOMIDE, Best Suoortive Care, Evidence Review Group, Acute Myeloid Leukemia, Appraisal Committee",
author = "Blommestein, {Hedwig M.} and Nigel Armstrong and Steve Ryder and Sohan Deshpande and Gill Worthy and Caro Noake and Rob Riemsma and Jos Kleijnen and Severens, {Johan L.} and Al, {Maiwenn J.}",
year = "2016",
month = "1",
doi = "10.1007/s40273-015-0318-3",
language = "English",
volume = "34",
pages = "23--31",
journal = "Pharmacoeconomics",
issn = "1170-7690",
publisher = "Adis International Ltd",
number = "1",

}

Lenalidomide for the Treatment of Low- or Intermediate-1-Risk Myelodysplastic Syndromes Associated with Deletion 5q Cytogenetic Abnormality : An Evidence Review of the NICE Submission from Celgene. / Blommestein, Hedwig M.; Armstrong, Nigel; Ryder, Steve; Deshpande, Sohan; Worthy, Gill; Noake, Caro; Riemsma, Rob; Kleijnen, Jos; Severens, Johan L.; Al, Maiwenn J.

In: Pharmacoeconomics, Vol. 34, No. 1, 01.2016, p. 23-31.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - Lenalidomide for the Treatment of Low- or Intermediate-1-Risk Myelodysplastic Syndromes Associated with Deletion 5q Cytogenetic Abnormality

T2 - An Evidence Review of the NICE Submission from Celgene

AU - Blommestein, Hedwig M.

AU - Armstrong, Nigel

AU - Ryder, Steve

AU - Deshpande, Sohan

AU - Worthy, Gill

AU - Noake, Caro

AU - Riemsma, Rob

AU - Kleijnen, Jos

AU - Severens, Johan L.

AU - Al, Maiwenn J.

PY - 2016/1

Y1 - 2016/1

KW - LENALIDOMIDE

KW - Best Suoortive Care

KW - Evidence Review Group

KW - Acute Myeloid Leukemia

KW - Appraisal Committee

U2 - 10.1007/s40273-015-0318-3

DO - 10.1007/s40273-015-0318-3

M3 - Article

VL - 34

SP - 23

EP - 31

JO - Pharmacoeconomics

JF - Pharmacoeconomics

SN - 1170-7690

IS - 1

ER -